Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Amanda Tobias

Physician Assistant Randolph, MA Physician Assistant

NPI 1700537776 CMS profile 11377624

32 S Main St, Randolph, MA 02368

Open in the dashboard

General payments

$961

38 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Tobias of Randolph, MA is reported in the CMS Open Payments database as having received $961 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $23 1
2023 General $258 8
2022 General $651 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Tobias
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amanda Tobias were reported at $28. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amanda Tobias Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $651 $155 $48–$522 $149
2023 $258 $167 $52–$557 $160
2024 $23 $178 $55–$600 $164
2025 $28 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Biohaven Pharmaceutical Holding Company Ltd. $186 12 payments
  2. Impel Pharmaceuticals Inc. $177 2 payments
  3. Sunovion Pharmaceuticals Inc. $123 2 payments
  4. UCB, Inc. $96 3 payments
  5. Neurocrine Biosciences, Inc. $69 4 payments
  6. Horizon Therapeutics plc $53 2 payments
  7. AbbVie, Inc. $48 3 payments
  8. Allergan Inc. $33 2 payments
  9. SK Life Science, Inc. $31 1 payment
  10. Eisai Inc. $28 1 payment
  11. Other $117 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $961 38 payments
Products named General payments · program years 2022–2025
  1. NURTEC ODT $186 12 payments
  2. APTIOM $123 2 payments
  3. Briviact $96 3 payments
  4. Trudhesa Neurology $95 1 payment
  5. Trudhesa Migraine $82 1 payment
  6. INGREZZA $69 4 payments
  7. Ongentys $69 4 payments
  8. UPLIZNA $53 2 payments
  9. BOTOX $33 2 payments
  10. QULIPTA $33 2 payments
  11. Other $169 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,188

Median for Physician Assistant: 241

Drug cost

$56,465

Median for Physician Assistant: $4,110

Branded share of claims

10.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 25 $32,963
Ozempic Semaglutide Brand 13 $10,644
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 15 $1,629
Atorvastatin Calcium Generic 103 $1,078
Fluticasone Propionate Generic 67 $886
Rosuvastatin Calcium Generic 70 $708
Levothyroxine Sodium Generic 70 $690
Ipratropium Bromide Generic 27 $634
Losartan Potassium Generic 75 $470
Synthroid Levothyroxine Sodium Brand 12 $452

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record